Russian government may consider re-purchase from Abbott

9 February 2015

The Russian government may consider the possibility of the re-purchase of the Russian pharmaceutical producer Veropharm that was recently acquired by the US drugmaker Abbott (NYSE: ABT), which announced the $495 million acquisition last year (The Pharma Lettr June 24, 2014).

According to Valery Rashkin and Sergei Obukhov, members of the Russian Parliament (State Duma), the sale of Veropharm to Abbott has negatively affected Russia’s national security in the field of pharmaceuticals, reports The Pharma Letter’s local correspondent.

According to the Russian State Duma, the deal may provide an opportunity for some Western countries to put a pressure on Russia and may lead to a shortage of drugs in the country.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK